New drug cocktail aims to tame rare blood cancers
NCT ID NCT05010005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 participants will take part, and researchers will also check if the combination helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ruxolitinib and duvelisib
- What this could lead to
- If successful, this could lead to a new treatment option for people with hard-to-treat T- or NK-cell lymphomas.
- What could go wrong
- This is an early Phase 1 trial with only 70 participants, so the drugs may not work or could have serious side effects. It is not yet known if the combination is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK-CELL LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
-
University of Miami (Data Collection Only)
ACTIVE_NOT_RECRUITINGMiami, Florida, 33125, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo aims to tackle tough lymphoma
- Massive T-Cell lymphoma database aims to unlock new insights
- Engineered donor cells take aim at tough blood cancers in early trial
- New hope for tough blood cancers: LP-118 trial launches
- New Two-Step transplant shows promise for blood cancer patients
- New drug cocktail aims to beat lymphoma without chemo